#1 Clinical Trials Search in Europe

Amphotericine B, Liposome

This article discusses clinical trials investigating the use of Amphotericin B, Liposome (also known as AmBisome) for treating fungal infections. These trials aim to evaluate the efficacy and safety of this medication compared to other treatments for conditions such as invasive aspergillosis and chronic pulmonary aspergillosis. The studies explore different administration methods and combination therapies to improve patient outcomes in various fungal infection scenarios.

Table of Contents

What is Amphotericin B, Liposome?

Amphotericin B, Liposome, also known as liposomal amphotericin B or by its brand name AmBisome, is a powerful antifungal medication used to treat serious fungal infections[1]. It is a specialized formulation of amphotericin B, where the drug is encased in tiny fat bubbles called liposomes. This liposomal formulation helps to reduce some of the side effects associated with traditional amphotericin B while maintaining its effectiveness against fungal infections.

Amphotericin B, Liposome is also referred to by several synonyms, including:

  • Liposomal Amphotericin B
  • Amphotericin B Liposome

Medical Conditions Treated

Amphotericin B, Liposome is primarily used to treat serious fungal infections, particularly those caused by Aspergillus species. Some of the conditions it is used to treat include:

  • Invasive aspergillosis: A severe fungal infection that can affect the lungs and other organs, particularly in people with weakened immune systems[1].
  • Chronic pulmonary aspergillosis (CPA): A long-term fungal infection of the lungs caused by Aspergillus[2].
  • Other invasive fungal infections

How It Works

Amphotericin B, Liposome works by disrupting the cell membranes of fungi. The liposomal formulation allows the drug to be delivered more effectively to the site of infection while reducing its impact on healthy human cells. This targeted approach helps to improve its efficacy and reduce potential side effects[1].

Administration and Dosage

Amphotericin B, Liposome is typically administered in the following ways:

  • Intravenous (IV) infusion: The most common method of administration is through an IV infusion. The typical dose is 3 mg/kg/day, given over a 30- to 60-minute period[1].
  • Nebulized form: In some cases, particularly for chronic pulmonary aspergillosis, it may be administered through nebulization (inhalation)[2].

The duration of treatment can vary depending on the specific condition and the patient’s response, but it typically ranges from 10 days to several weeks or even months in some cases[1].

Effectiveness

Amphotericin B, Liposome has shown significant effectiveness in treating invasive fungal infections, particularly those caused by Aspergillus species. In clinical trials, it has demonstrated comparable or superior efficacy to other antifungal treatments, with the added benefit of potentially fewer side effects due to its liposomal formulation[1].

Side Effects and Safety

While Amphotericin B, Liposome is generally better tolerated than conventional amphotericin B, it can still cause side effects. Some potential side effects include:

  • Kidney problems
  • Liver function abnormalities
  • Electrolyte imbalances
  • Infusion-related reactions (fever, chills, nausea)

Patients should be closely monitored during treatment, and regular blood tests may be necessary to check kidney and liver function[1].

Ongoing Research

Ongoing research is exploring new ways to use Amphotericin B, Liposome and comparing its effectiveness to other antifungal treatments. For example:

  • A study is comparing the effectiveness of nebulized Amphotericin B, Liposome combined with oral itraconazole versus itraconazole alone for treating chronic pulmonary aspergillosis[2].
  • Another study is comparing Amphotericin B, Liposome to a new antifungal drug called olorofim for treating invasive aspergillosis[1].

These studies aim to further improve treatment options for patients with serious fungal infections and to better understand the role of Amphotericin B, Liposome in different treatment strategies.

Aspect Details
Drug Name Amphotericin B, Liposome (AmBisome)
Conditions Studied Invasive Aspergillosis, Chronic Pulmonary Aspergillosis
Administration Methods Intravenous infusion, Nebulized (inhaled)
Comparisons Olorofim, Itraconazole alone
Primary Endpoints All-cause mortality, Therapeutic efficacy (clinical and radiological improvement)
Secondary Endpoints Overall response, Survival time, Quality of life, Mycological response
Patient Population Adults with specific fungal infections, varying levels of immunocompromise
Treatment Duration 6 months to 84 days, with follow-up periods
Safety Monitoring Clinical and biological tolerance, adverse events

FAQ

  • What is Amphotericin B, Liposome used for in these clinical trials? Amphotericin B, Liposome (AmBisome) is being studied for treating various fungal infections, particularly invasive aspergillosis and chronic pulmonary aspergillosis. It's being compared to other antifungal treatments and explored in different administration methods to determine its effectiveness and safety.
  • How is Amphotericin B, Liposome administered in these trials? In the trials, Amphotericin B, Liposome is administered in different ways. One study uses it as an intravenous infusion at a dose of 3 mg/kg/day. Another trial explores its use as a nebulized (inhaled) treatment in combination with oral itraconazole.
  • What are the main objectives of these clinical trials? The main objectives include comparing the efficacy and safety of Amphotericin B, Liposome to other treatments, evaluating its effectiveness in different types of fungal infections, and assessing patient outcomes such as mortality rates, overall response, and quality of life improvements.
  • Who are the typical participants in these Amphotericin B, Liposome trials? Participants are generally adults (18 years or older) diagnosed with specific fungal infections like invasive aspergillosis or chronic pulmonary aspergillosis. The trials have various inclusion and exclusion criteria, such as certain levels of organ function and absence of severe immunosuppression in some cases.
  • What are some of the potential side effects or risks associated with Amphotericin B, Liposome in these trials? While specific side effects aren't detailed in the trial summaries, the studies monitor for clinical and biological tolerance. Patients with certain conditions like severe renal failure, liver dysfunction, or history of hypersensitivity to the drug are typically excluded. The trials also assess safety and tolerability as part of their objectives.

Ongoing Clinical Trials on Amphotericine B, Liposome

  • A study to compare the effectiveness of EL219 against liposomal amphotericin B and voriconazole for patients with suspected invasive mould infections.

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium France Italy Spain

  • Study Comparing Itraconazole and Nebulised Amphotericin B with Itraconazole Alone for Patients with Chronic Pulmonary Aspergillosis

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study comparing 7-day versus 14-day antifungal treatment for patients with uncomplicated candidemia using fluconazole, anidulafungin, or other medications

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Olorofim vs. Liposomal Amphotericin B for Patients with Invasive Aspergillosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

Glossary

  • Invasive Aspergillosis (IA): A serious fungal infection caused by Aspergillus species, typically affecting the lungs and potentially spreading to other organs, especially in immunocompromised patients.
  • Chronic Pulmonary Aspergillosis (CPA): A long-term fungal infection of the lungs caused by Aspergillus species, often occurring in patients with pre-existing lung conditions.
  • Liposomal: A drug delivery method where the medication is encapsulated in tiny fat bubbles, which can improve its distribution in the body and potentially reduce side effects.
  • Galactomannan (GM): A molecule found in the cell wall of Aspergillus fungi, used as a biomarker to diagnose and monitor invasive aspergillosis.
  • Mycological response: The effectiveness of treatment in eliminating or reducing the presence of fungi, as measured by laboratory tests.
  • All-cause mortality (ACM): The death rate from any cause in a group of patients, used as a measure of overall treatment effectiveness.
  • Nebulized: A method of delivering medication as a fine mist that can be inhaled into the lungs.
  • QTc interval: A measure of the heart's electrical activity on an ECG, used to assess the risk of certain heart rhythm abnormalities.
  • Standard of Care (SOC): The currently accepted treatment approach for a specific condition, used as a comparison for new treatments in clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-olorofim-vs-liposomal-amphotericin-b-for-patients-with-invasive-aspergillosis/
  2. http://clinicaltrials.eu/trial/study-comparing-itraconazole-and-nebulised-amphotericin-b-with-itraconazole-alone-for-patients-with-chronic-pulmonary-aspergillosis/